Use of tadalafil in a patient with a secondary Raynaud's phenomenon not responding to sildenafil.
The Raynaud's phenomenon often accompanies systemic rheumatic diseases and is also known as a vascular side effect of chemotherapy. Therapy of the Raynaud's phenomenon with nitrates or calcium-channel-blockers is rarely beneficial. In contrast, the PDE-V-inhibitor sildenafil seems to be effective in these patients. For the first time we report on a patient with Raynaud's phenomenon due to chemotherapy not responding to sildenafil but to the new PDE-V-inhibitor tadalafil in an equivalent dosage. Measurement with a laser Doppler revealed an increased blood flow and a reduction of symptoms. Therefore, therapy of Raynaud's phenomenon with the new PDE-V-inhibitor tadalafil seems to be an effective treatment option in patients not responding to sildenafil.
Baumhaekel
Magnus
M
Department of Cardiology and Angiology, University Hospital of the Saarland, Kirrbergerstr., 66421 Homburg/Saar, Germany. magnus@baumhaekel.de
Scheffler
Peter
P
Boehm
Michael
M
D015106:3',5'-Cyclic-GMP Phosphodiesterases / Q000037:antagonists & inhibitors; D001916:Brachial Artery / Q000000981:diagnostic imaging / Q000473:pathology; D002196:Capillaries / Q000187:drug effects; D002243:Carbolines / Q000627:therapeutic use*; D005385:Fingers / Q000098:blood supply / Q000000981:diagnostic imaging; D006801:Humans; D017078:Laser-Doppler Flowmetry; D008297:Male; D008875:Middle Aged; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use*; D010879:Piperazines / Q000627:therapeutic use*; D011687:Purines; D011928:Raynaud Disease / Q000188:drug therapy* / Q000209:etiology; D012039:Regional Blood Flow / Q000187:drug effects; D000068677:Sildenafil Citrate; D013450:Sulfones; D000068581:Tadalafil; D016896:Treatment Outcome; D014463:Ultrasonography
D002243:Carbolines; D010726:Phosphodiesterase Inhibitors; D010879:Piperazines; D011687:Purines; D013450:Sulfones; D000068581:Tadalafil; D000068677:Sildenafil Citrate; D015106:3',5'-Cyclic-GMP Phosphodiesterases